Literature DB >> 17004013

Scoring of KDR kinase inhibitors: using interaction energy as a guide for ranking.

Georgia B McGaughey1, J Chris Culberson, Bradley P Feuston, Constantine Kreatsoulas, Vladimir Maiorov, Joseph Shpungin.   

Abstract

Within a congeneric series of ATP-competitive KDR kinase inhibitors, we determined that the IC(50) values, which span four orders of magnitude, correlated best with the calculated ligand-protein interaction energy using the Merck Molecular Force Field (MMFFs(94)). Using the ligand-protein interaction energy as a guide, we outline a workflow to rank order virtual KDR kinase inhibitors prior to synthesis. When structural information of the target is available, the ability to score molecules a priori can be used to rationally select reagents. Our implementation allows one to select thousands of readily available reagents, enumerate compounds in multiple poses and score molecules in the active site of a protein within a few hours. In our experience, virtual library enumeration is best used when a correlation between computed descriptors/properties and IC(50) or K (i) values has been established.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004013     DOI: 10.1007/s11030-006-9037-1

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  14 in total

Review 1.  Regulation of angiogenesis via vascular endothelial growth factor receptors.

Authors:  T Veikkola; M Karkkainen; L Claesson-Welsh; K Alitalo
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

2.  Comparison of knowledge-based and distance geometry approaches for generation of molecular conformations.

Authors:  B P Feuston; M D Miller; J C Culberson; R B Nachbar; S K Kearsley
Journal:  J Chem Inf Comput Sci       Date:  2001 May-Jun

Review 3.  Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.

Authors:  George D Hartman; Mark E Fraley; Mark T Bilodeau
Journal:  Expert Opin Investig Drugs       Date:  2002-06       Impact factor: 6.206

4.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction.

Authors:  Renxiao Wang; Luhua Lai; Shaomeng Wang
Journal:  J Comput Aided Mol Des       Date:  2002-01       Impact factor: 3.686

5.  Reagent Selector: using Synthon Analysis to visualize reagent properties and assist in combinatorial library design.

Authors:  Ralph T Mosley; J Christopher Culberson; Bryan Kraker; Bradley P Feuston; Robert P Sheridan; John F Conway; Joseph K Forbes; Subhas J Chakravorty; Simon K Kearsley
Journal:  J Chem Inf Model       Date:  2005 Sep-Oct       Impact factor: 4.956

6.  The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.

Authors:  A Giatromanolaki; E Sivridis; N Athanassou; E Zois; P E Thorpe; R A Brekken; K C Gatter; A L Harris; I M Koukourakis; M I Koukourakis
Journal:  J Pathol       Date:  2001-05       Impact factor: 7.996

7.  Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.

Authors:  M A McTigue; J A Wickersham; C Pinko; R E Showalter; C V Parast; A Tempczyk-Russell; M R Gehring; B Mroczkowski; C C Kan; J E Villafranca; K Appelt
Journal:  Structure       Date:  1999-03-15       Impact factor: 5.006

8.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.

Authors:  F Shalaby; J Rossant; T P Yamaguchi; M Gertsenstein; X F Wu; M L Breitman; A C Schuh
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

Review 9.  Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.

Authors:  Stephen J Boyer
Journal:  Curr Top Med Chem       Date:  2002-09       Impact factor: 3.295

10.  The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.

Authors:  Mark T Bilodeau; Leonard D Rodman; Georgia B McGaughey; Kathleen E Coll; Timothy J Koester; William F Hoffman; Randall W Hungate; Richard L Kendall; Rosemary C McFall; Keith W Rickert; Ruth Z Rutledge; Kenneth A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2004-06-07       Impact factor: 2.823

View more
  1 in total

1.  SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK).

Authors:  Keith R Laderoute; Joy M Calaoagan; Peter B Madrid; Anthony E Klon; Paula J Ehrlich
Journal:  Cancer Biol Ther       Date:  2010-07-26       Impact factor: 4.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.